Sep 14, 2026 —
Cellectis is leaving cell therapy behind and remaking itself around in vivo gene editing. The company is discontinuing its two allogeneic CAR-T candidates, lasme-cel and eti-cel, citing a materially changed landscape for blood cancers as frontline regimens improve and bispecific antibodies and in vivo CAR-T crowd the later-line settings.
In their place, Cellectis is advancing two liver-directed programs built on its TALEN base-editing technology, formulated in lipid nanoparticles and given intravenously. The approach edits without cutting both strands of DNA, avoiding the double-strand breaks associated with conventional CRISPR nucleases.
HEAL-101 targets APOC3 for severe hypertriglyceridemia and reduced triglycerides by about 76% in mouse models, with first Phase 1 data expected in the second half of 2027. HEAL-201 targets the PCSK9 promoter for severe hypercholesterolemia and lowered plasma PCSK9 by more than 90% in mice, with Phase 1 data expected in the first half of 2028.
